Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 1105-1109

  Infante, Jon ^a,b   Prieto, Carlos ^c   Sierra, María ^a,b   Sánchez Juan, Pascual ^a,b   González Aramburu, Isabel ^a,b   Sánchez Quintana, Coro ^a   Berciano, José ^a,b   Combarros, Onofre ^a,b   Sainz, Jesús ^c  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c CSIC   (Spain)

Author keywords

Gene expression; LRRK2; Parkinson's disease; Peripheral blood; RNA seq; Transcriptome

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; LEUCINE RICH REPEAT KINASE 2; TRANSCRIPTOME; LRRK2 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE;

ADARB2 GENE; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CEACAM6 GENE; CLINICAL ARTICLE; CNTNAP2 GENE; COL19A1 GENE; CONTROLLED STUDY; DEF4 GENE; DRAXIN GENE; FCER2 GENE; FEMALE; G2019S GENE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GLUCOSE METABOLISM; HBG1 GENE; HUMAN; IDIOPATHIC DISEASE; LRRK2 GENE; MALE; NCAPG2 GENE; NEUROPATHOLOGY; PARKINSON DISEASE; PVRL2 GENE; RNA SEQUENCE; SIGNAL TRANSDUCTION; SLC2A14 GENE; SNCA GENE; TCL1B GENE; GENETICS; HETEROZYGOTE; MIDDLE AGED; MUTATION; PROCEDURES; SEQUENCE ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; GENETIC ASSOCIATION STUDIES; GENOME-WIDE ASSOCIATION STUDY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA;

EID: 84922786331     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.039     Document Type: Article

References (33)

1. Abbott R.D., Ross G.W., Tanner C.M., Andersen J.K., Masaki K.H., Rodriguez B.L., White L.R., Petrovitch H. Late-life hemoglobin and the incidence of Parkinson's disease. Neurobiol. Aging 2012, 33:914-920.
2. Ahmed G., Shinmyo Y., Ohta K., Islam S.M., Hossain M., Naser I.B., Riyadh M.A., Su Y., Zhang S., Tessier-Lavigne M., Tanaka H. Draxin inhibits axonal outgrowth through the netrin receptor DCC. J.Neurosci. 2011, 31:14018-14023.
3. Beilina A., Rudenko I.N., Kaganovich A., Civiero L., Chau H., Kalia S.K., Lobbestael E., Chia R., Ndukwe K., Ding J., Nalls M.A., Olszewski M., Hauser D.N., Kumaran R., Lozano A.M., Baekelandt V., Greene L.E., Taymans J.M., Greggio E., Cookson M.R. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl. Acad. Sci. U. S. A 2014, 111:2626-2631. International Parkinson's Disease Genomics Consortium, North American Brain Expression ConsortiumNorth American Brain Expression Consortium.
4. Calvo A.C., Manzano R., Atencia-Cibreiro G., Oliván S., Muñoz M.J., Zaragoza P., Cordero-Vázquez P., Esteban-Pérez J., García-Redondo A., Osta R. Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice. PLoS One 2012, 7:e32632.
5. Cooper-Knock J., Kirby J., Ferraiuolo L., Heath P.R., Rattray M., Shaw P.J. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 2012, 8:518-530.
6. Dunn L., Allen G.F., Mamais A., Ling H., Li A., Duberley K.E., Berg D., Mueller J.C., Gasser T., Hargreaves I.P., Pope S., Holton J.L., Lees A., Heales S.J., Bandopadhyay R. Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiol. Aging 2014, 35:1111-1115.
7. Fuchs J., Tichopad A., Golub Y., Munz M., Schweitzer K.J., Wolf B., Berg D., Mueller J.C., Gasser T. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008, 22:1327-1334.
8. Gorostidi A., Bergareche A., Ruiz-Martínez J., Martí-Massó J.F., Cruz M., Varghese S., Qureshi M.M., Alzahmi F., Al-Hayani A., López de Munáin A., El-Agnaf O.M. Alpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One 2012, 7:e52312.
9. Greene L.A., Levy O., Malagelada C. Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol. Neurobiol. 2011, 31:969-978.
10. Hamza T.H., Payami H. The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. J.Hum. Genet. 2010, 55:241-243.
11. Hashimoto M., Suizu F., Tokuyama W., Noguchi H., Hirata N., Matsuda-Lennikov M., Edamura T., Masuzawa M., Gotoh N., Tanaka S., Noguchi M. Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency invivo. Oncogenesis 2013, 2:e70.
12. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira A.H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., Wood N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590. International LRRK2 Consortium.
13. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debré P., Agid Y., Dugas B., Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, invitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J.Neurosci. 1999, 19:3440-3447.
14. Kannarkat G.T., Boss J.M., Tansey M.G. The role of innate and adaptive immunity in Parkinson's disease. J.Parkinsons Dis. 2013, 3:493-514.
15. Liew C.C., Ma J., Tang H.C., Zheng R., Dempsey A.A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J.Lab. Clin. Med. 2006, 147:126-132.
16. Logue M.W., Schu M., Vardarajan B.N., Buros J., Green R.C., Go R.C., Griffith P., Obisesan T.O., Shatz R., Borenstein A., Cupples L.A., Lunetta K.L., Fallin M.D., Baldwin C.T., Farrer L.A. Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group. A comprehensive genetic association study of Alzheimer disease in African Americans. Arch. Neurol. 2011, 68:1569-1579.
17. Mezey E., Dehejia A.M., Harta G., Tresser N., Suchy S.F., Nussbaum R.L., Brownstein M.J., Polymeropoulos M.H. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol. Psychiatry 1998, 3:493-499.
18. Mutez E., Nkiliza A., Belarbi K., de Broucker A., Vanbesien-Mailliot C., Bleuse S., Duflot A., Comptdaer T., Semaille P., Blervaque R., Hot D., Leprêtre F., Figeac M., Destée A., Chartier-Harlin M.C. Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease. Neurobiol. Dis. 2014, 63:165-170.
19. Pankratz N., Beecham G.W., DeStefano A.L., Dawson T.M., Doheny K.F., Factor S.A., Hamza T.H., Hung A.Y., Hyman B.T., Ivinson A.J., Krainc D., Latourelle J.C., Clark L.N., Marder K., Martin E.R., Mayeux R., Ross O.A., Scherzer C.R., Simon D.K., Tanner C., Vance J.M., Wszolek Z.K., Zabetian C.P., Myers R.H., Payami H., Scott W.K., Foroud T. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann. Neurol. 2012, 71:370-384. PD GWAS Consortium.
20. Pchelina S.N., Emelyanov A.K., Yakimovskii A.F., Miller D.W., Shabalina I.G., Drozdova A.S., Schwarzman A.L. Reduced content of α-synuclein in peripheral blood leukocytes of patients with LRRK2-associated Parkinson's disease. Bull Exp. Biol. Med. 2011, 150:679-681.
21. Peñagarikano O., Abrahams B.S., Herman E.I., Winden K.D., Gdalyahu A., Dong H., Sonnenblick L.I., Gruver R., Almajano J., Bragin A., Golshani P., Trachtenberg J.T., Peles E., Geschwind D.H. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 2011, 147:235-246.
22. Perry R.T., Gearhart D.A., Wiener H.W., Harrell L.E., Barton J.C., Kutlar A., Kutlar F., Ozcan O., Go R.C., Hill W.D. Hemoglobin binding to A beta and HBG2 SNP association suggest a role in Alzheimer's disease. Neurobiol. Aging 2008, 29:185-193.
23. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
24. Scherzer C.R., Eklund A.C., Morse L.J., Liao Z., Locascio J.J., Fefer D., Schwarzschild M.A., Schlossmacher M.G., Hauser M.A., Vance J.M., Sudarsky L.R., Standaert D.G., Growdon J.H., Jensen R.V., Gullans S.R. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:955-960.
25. Sebastiani P., Montano M., Puca A., Solovieff N., Kojima T., Wang M.C., Melista E., Meltzer M., Fischer S.E., Andersen S., Hartley S.H., Sedgewick A., Arai Y., Bergman A., Barzilai N., Terry D.F., Riva A., Anselmi C.V., Malovini A., Kitamoto A., Sawabe M., Arai T., Gondo Y., Steinberg M.H., Hirose N., Atzmon G., Ruvkun G., Baldwin C.T., Perls T.T. RNA editing genes associated with extreme old age in humans and with lifespan in C. elegans. PLoS One 2009, 4:e8210.
26. Shulman J.M., Chipendo P., Chibnik L.B., Aubin C., Tran D., Keenan B.T., Kramer P.L., Schneider J.A., Bennett D.A., Feany M.B., DeJager P.L. Functional screening of Alzheimer pathology genome-wide association signals in Drosophila. Am. J. Hum. Genet. 2011, 88:232-238.
27. Sierra M., González-Aramburu I., Sánchez-Juan P., Sánchez-Quintana C., Polo J.M., Berciano J., Combarros O., Infante J. High frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in Cantabria (Spain). Mov. Disord. 2011, 26:2343-2346.
28. Singh M. Dysregulated A to I RNA editing and non-coding RNAs in neurodegeneration. Front. Genet. 2013, 3:326.
29. Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 2013, 28:14-23.
30. Su J., Gorse K., Ramirez F., Fox M.A. Collagen XIX is expressed by interneurons and contributes to the formation of hippocampal synapses. J.Comp. Neurol. 2010, 518:229-253.
31. Thenganatt M.A., Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014, 71:499-504.
32. Valente E.M., Arena G., Torosantucci L., Gelmetti V. Molecular pathways in sporadic PD. Parkinsonism Relat. Disord. 2012, 18(Suppl 1):S71-S73.
33. van Abel D., Michel O., Veerhuis R., Jacobs M., van Dijk M., Oudejans C.B. Direct downregulation of CNTNAP2 by STOX1A is associated with Alzheimer's disease. J.Alzheimers Dis. 2012, 31:793-800.